C18 Ceramide (d18:1/18:0)
(Synonyms: N-硬脂酰神经鞘氨醇) 目录号 : GC43047C18 Ceramide (d18:1/18:0)是Ceramide在细胞内经过代谢产生的一种内源性生物活性鞘脂，可通过血脑屏障，是海马区受损后产生的主要神经酰胺。
Cas No.:2304-81-6
Sample solution is provided at 25 µL, 10mM.
C18 Ceramide (d18:1/18:0) is an endogenous bioactive sphingolipid produced by the metabolism of Ceramide within cells. It can cross the blood-brain barrier and is the main ceramide produced after damage to the hippocampal region [1-2]. Ceramide is an important signaling sphingolipid involved in cell growth arrest, differentiation, and apoptosis. C18 Ceramide induces cell death, promotes autophagy, and enhances exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft-related functions [3-4]. C18 Ceramide has anti-cancer functions and can be used in the research of cancer such as glioma and mechanisms of neuronal damage [5].
In vitro, treatment with C18 Ceramide (20μM; 48h) significantly inhibited the cell viability of U251 and A172 glioma cells overexpressing CERS1, induced cell death, and activated endoplasmic reticulum stress, increasing the mRNA and protein levels of ATF-4, XBP-1(s), and CHOP [4]. Treatment with C18 Ceramide (0.01, 0.1, and 10μM; 4d) on osteoclasts and osteoblasts significantly promoted the formation of differentiated osteoblasts, increased the generation of osteoblasts and the expression levels of osteoclast differentiation markers (such as Trap, Ctr, Mmp9, and Catk) [6].
In vivo, C18 Ceramide (5mg/kg/day; 10d; i.p.) treatment significantly alleviated bile-accumulation-induced liver injury (CLI) in wild-type (WT) female mice, increased the level of C18 Ceramide in the liver, and significantly elevated the expression of nuclear Lxrβ and Sult2a1 in liver cells, as well as the mRNA levels of Scd1 and Fasn [7].
References:
[1] Tang N, et al. Differential effects of ceramide species on exocytosis in rat PC12 cells. Exp Brain Res. 2007 Nov;183(2):241-7.
[2] Mizutani, Y., Kihara, A., and Igarashi, Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J. 390(Pt. 1), 263-271 (2005).
[3] Chen L, Chen H, Li Y, et al. Endocannabinoid and ceramide levels are altered in patients with colorectal cancer[J]. Oncology reports, 2015, 34(1): 447-454.
[4] Wang Z, et al. Overexpression of ceramide synthase 1 increases C18-ceramide and leads to lethal autophagy in human glioma. Oncotarget. 2017 Oct 23;8(61):104022-104036.
[5] Saddoughi S A, Garrett-Mayer E, Chaudhary U, et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response[J]. Clinical Cancer Research, 2011, 17(18): 6097-6105.
[6] Kim B J, Lee J Y, Park S J, et al. Elevated ceramides 18: 0 and 24: 1 with aging are associated with hip fracture risk through increased bone resorption[J]. Aging (Albany NY), 2019, 11(21): 9388.
[7] Liao L, Liu Z, Liu L, et al. Targeting the ceramidase ACER3 attenuates cholestasis in mice by mitigating bile acid overload via unsaturated ceramide-mediated LXRβ signaling transduction[J]. Nature Communications, 2025, 16(1): 2112.
C18 Ceramide (d18:1/18:0)是Ceramide在细胞内经过代谢产生的一种内源性生物活性鞘脂，可通过血脑屏障，是海马区受损后产生的主要神经酰胺 [1-2]。神经酰胺是参与细胞生长停滞、分化和细胞凋亡的重要信号鞘脂。C18 Ceramide通过激活内质网应激、抑制PI3K/AKT信号通路以及影响脂质筏相关功能等机制，诱导细胞死亡、促进自噬、增强胞吐 [3-4]。C18 Ceramide具有抑癌功能，可用于胶质瘤等癌症和神经元损伤机制研究 [5]。
在体外，C18 Ceramide (20μM; 48h)处理显著抑制了CERS1过表达的U251和A172胶质瘤细胞的细胞活力，诱导细胞死亡并激活内质网应激，增加了ATF-4、XBP-1(s)和CHOP的mRNA和蛋白水平[4]。C18 Ceramide（0.01、0.1和10μM; 4d）处理破骨细胞和成骨细胞，显著促进了分化成骨细胞的形成，增加成骨细胞的生成和骨吸收细胞分化标志物（如Trap、Ctr、Mmp9和Catk）的表达水平 [6]。
在体内，C18 Ceramide（5mg/kg/day; 10d; i.p.）处理显著减弱了野生型（WT）雌性小鼠的胆汁淤积性肝损伤（CLI），升高了肝脏中C18 Ceramide水平，肝细胞中核Lxrβ、Sult2a1的表达和Scd1、Fasn的mRNA水平也显著升高 [7]。
| Cell experiment [1]: | |
Cell lines | Human glioma cell lines (A172 and U251) |
Preparation Method | A172 and U251 cells were cultured in Dulbecco’s modified Eagle’s medium, with 10% fetal bovine serum, 100units/mL penicillin and streptomycin, 2mM L-glutamine, and nonessential amino acids, and cells were incubated in a 37°C incubator in an atmosphere of 5% CO2. The C18 Ceramide was dissolved with DMSO at stock concentration of 50mM, and diluted to work concentration (20μM) with DMEM medium. The C18 Ceramide treatment was adding the C18 Ceramide solution (diluted with DMEM medium) to the cells, and the control was the same volume of DMSO. The CCK-8 assay was used to measure the effect of C18 Ceramide on cell viability. Protein blotting analysis was performed to detect the expression levels of ATF-4, XBP-1 (s) and CHOP in U251 and A172 cells after overexpression of CERS1. |
Reaction Conditions | 20μM; 48h |
Applications | C18 Ceramide significantly inhibited the cell viability of U251 and A172 glioma cells with overexpressed CERS1, and increased the mRNA and protein levels of ATF-4, XBP-1(s) and CHOP. |
| Animal experiment [2]: | |
Animal models | C57BL/6 J mice |
Preparation Method | C57BL/6 J female mice were intraperitoneally injected with 5mg/kg/day C18 Ceramide dissolved in 0.5% sodium carboxymethylcellulose (CMC-Na), and 0.5% CMC-Na was used as vehicle control. C18 Ceramide treatment was performed once every day for 10 days, and bile duct ligation (BDL) was performed on the third day. BDL was conducted to induce bile-duct-obstructive liver injury (CLI) in eight-week-old mice, while Sham operation was used as control. The procedures of BDL were performed with midventral laparotomy and the isolation of the common bile duct above the duodenum, then the common bile duct was ligated at two sites to induce obstructive cholestasis. Mice were sacrificed 7 days after the BDL operation. The tissues and serum were collected and stored at -80°C. Liver tissues were fixed in 4% paraformaldehyde (PFA) or Tissue-Tek OCT compound for pathophysiological examination. |
Dosage form | 5mg/kg/day; 10d; i.p. |
Applications | C18 Ceramide significantly alleviated CLI and increased the level of C18 Ceramide in the liver, and also significantly elevated the expression of nuclear Lxrβ and Sult2a1 in liver cells, as well as the mRNA levels of Scd1 and Fasn. |
References: | |
| Cas No. | 2304-81-6 | SDF | |
| 别名 | N-硬脂酰神经鞘氨醇 | ||
| 化学名 | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-octadecanamide | ||
| Canonical SMILES | OC[C@H](NC(CCCCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC | ||
| 分子式 | C36H71NO3 | 分子量 | 566 |
| 溶解度 | 0.15mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7668 mL | 8.8339 mL | 17.6678 mL |
| 5 mM | 0.3534 mL | 1.7668 mL | 3.5336 mL |
| 10 mM | 0.1767 mL | 0.8834 mL | 1.7668 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet